BAMOS project is funded under the Research and Innovation Staff Exchanges (RISE) action (H2020 Marie Skłodowska-Curie actions), which supports short-term mobility of research and innovation staff at all career levels, from the most junior (post-graduate) to the most senior, including also administrative and technical staff. It is open to partnerships of universities, research institutions, and non-academic organisations both within and beyond Europe. The partners propose an integrated programme of research activities and the development of a collaborative graduate training scheme.
Osteoarthritis (OA) is a degenerative joint disease, typified by a loss of quality of cartilage and changes in bone at the interface of a joint, resulting in pain, stiffness and reduced mobility. The project Biomaterials and Additive Manufacturing: Osteochondral Scaffold (BAMOS) innovation applied to osteoarthritis particularly addresses the challenges in OA treatment by providing novel cost effective osteochondral scaffold technology for early intervention of OA to delay or avoid the joint replacement operations. This project has the potential to relieve pain in patients with OA improving their quality of life by keeping people active. It fits with the scope of EU Societal Challenges to encourage the provision of improved clinical care for patients in the field of healthcare, especially for elderly patients. In the course of developing this new treatment for mid- to late stage OA, BAMOS aims to establish and embed a new collaboration between seven internationally leading research organisations (from Europe and China).
BAMOS will develop new materials and additive manufacturing technologies for the fabrication of custom-tailored osteochondral scaffolds. The new technologies will undergo full pre-clinical evaluation in order that the scaffolds are able to enter clinical trial after the project.